Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data


Charles River Laboratories International, Inc. (NYSE: CRL) today launched Apollo™, an industry-leading, secure, cloud-based platform for drug developers that provides access to study data, study

Premier, Inc. Named One of the 2023 World’s Most Ethical Companies® by Ethisphere® for 16th Consecutive Year: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Named One of the 2023 World’s Most Ethical Companies® by Ethisphere® for 16th Consecutive Year


Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been recognized by Ethisphere®, a global leader in defining and advancing the standards of ethical

Charles River Laboratories to Present at Barclays Global Healthcare Conference: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories to Present at Barclays Global Healthcare Conference


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15th, at 10:15 a.m. ET. Management

Pfizer Invests $43 Billion to Battle Cancerhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invests $43 Billion to Battle Cancer


Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology

DexCom Comments on SVB Relationship: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
DexCom Comments on SVB Relationship


DexCom, Inc. (NASDAQ: DXCM), today issued the following statement in response to speculation following the developments at Silicon Valley Bank, including a recent CNBC article:



“Dexcom does not

Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023:
Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023


Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated end-to-end solution for digital pathology that brings together best-in-class products from Agilent, Visiopharm, Proscia®

Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023:
Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023


Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated end-to-end solution for digital pathology that brings together best-in-class products from Agilent, Visiopharm, Proscia®

Agilent Announces Digital Pathology Scanner Distribution Agreement with Hamamatsu:
Agilent Announces Digital Pathology Scanner Distribution Agreement with Hamamatsu


Agilent Technologies Inc. (NYSE: A) today announced it has partnered with Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems, to incorporate their NanoZoomer range

Agilent Announces Digital Pathology Scanner Distribution Agreement with HamamatsuPexels:
Agilent Announces Digital Pathology Scanner Distribution Agreement with Hamamatsu


Agilent Technologies Inc. (NYSE: A) today announced it has partnered with Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems, to incorporate their NanoZoomer range

Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approvalhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval


Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor

Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approvalhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval


Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor

Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics, Inc.
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics, Inc.
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics, Inc.
Agilent Again Named One of Barron’s 100 Most Sustainable Companies: https://unsplash.com/photos/WUehAgqO5hE
Agilent Again Named One of Barron’s 100 Most Sustainable Companies


For the sixth consecutive year, Agilent Technologies (NYSE: A) is ranked among the top 20 in Barron’s list of America’s 100 Most Sustainable Companies.



The ranking is based on the performance of

Agilent Announces Acquisition of e-MSion, Early-Stage Company Behind ECD Technology that Helps Accelerate Drug Development:
Agilent Announces Acquisition of e-MSion, Early-Stage Company Behind ECD Technology that Helps Accelerate Drug Development


Agilent Technologies Inc. (NYSE: A) today announced the acquisition of e-MSion, an early-stage company behind the innovative electron capture dissociation (ECD) technology known as the ExD cell.

Humana’s Economic Impact in Florida Totals $48 Billion: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana’s Economic Impact in Florida Totals $48 Billion


An independent economic research analysis estimated that leading health and well-being company Humana Inc. (NYSE: HUM) would contribute a total of $48 billion in overall economic impact in the

Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite™ in Version 2023R1


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Lixoft division, a leading

Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus

QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA


QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine

NanoString Reports Inducement Grants Under Nasdaq Listing Rules: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Reports Inducement Grants Under Nasdaq Listing Rules


NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity

Humana Healthy Horizons Recommended by Indiana Family and Social Services Administration to Serve Medicaid Beneficiaries: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Healthy Horizons Recommended by Indiana Family and Social Services Administration to Serve Medicaid Beneficiaries


Leading integrated health and wellness company Humana Inc. (NYSE: HUM) has been notified by the Indiana Family and Social Services Administration (FSSA) that FSSA is recommending Humana be awarded

Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder


Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system

Inogen to Present at KeyBanc Life Sciences & MedTech Investor Forum: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen to Present at KeyBanc Life Sciences & MedTech Investor Forum


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will participate in a virtual

Agilent Announces Global Distribution Agreement with Proscia to Accelerate Data-Driven Precision Medicine: https://unsplash.com/photos/WUehAgqO5hE
Agilent Announces Global Distribution Agreement with Proscia to Accelerate Data-Driven Precision Medicine


Agilent Technologies Inc. (NYSE: A) today announced a multi-year distribution agreement with Proscia® – a leader in digital pathology – to offer a comprehensive digital diagnostic pathology system

Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting

Premier Inc. to Participate in Barclays Global Healthcare Conference on March 14, 2023: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. to Participate in Barclays Global Healthcare Conference on March 14, 2023


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the Barclays